HoldsUp

DavidPerlmutterMD · 2026-04-28 · David Perlmutter (host), Barnet Bain

Why Modern Life Is Making Real Connection Harder | Barnet Bain

10 research-tied claims examined: 1 contradicted 1 overstated 8 supported

1

Contradicted by research

1:04:00David Perlmutter (host)contradictedmoderate

When you exercise a muscle, you tear the muscle fibers, which build back stronger to increase muscle mass.

"When you exercise a muscle, you tear the muscle fibers, they build back stronger, and that's how you gain muscle mass." (said at 1:04:00)

The classic idea that resistance training causes muscle growth by creating microscopic tears in muscle fibers that 'build back stronger' is contradicted by modern exercise physiology. Research demonstrates that exercise-induced muscle damage is not the primary driver or prerequisite for muscle hypertrophy. Instead, mechanical tension stimulates intracellular signaling pathways that elevate muscle protein synthesis (MPS) above muscle protein breakdown. When muscle damage is high, early elevations in protein synthesis are directed toward repairing and remodeling damaged tissue rather than accumulating new contractile protein. Substantial hypertrophy occurs when muscle damage is minimal or attenuated, and training regimens designed to minimize microtrauma induce comparable hypertrophy to damage-inducing protocols.

1

Overstated

0:22:23David Perlmutter (host)overstatedvery low

Optoceutics' 40 Hz light technology achieves a 94% adherence rate and produces significant improvements across metrics including mood, energy, focus, sleep, and memory.

"So, there is a company called Optoceutics. They've solved this problem with a patented technology that still gives you the 40 Hz light flashing, but through light that looks and feels quite normal. It's the device I actually have on my desk when I'm working, and that's why this company sees a 94% adherence rate and significant improvements across various metrics, including mood, energy, focus, sleep, and memory." (said at 0:22:23)

Optoceutics developed an invisible spectral flicker (ISF) light technology designed to entrain 40 Hz gamma oscillations with less visual discomfort than stroboscopic flicker. However, claims of proven significant improvements across mood, energy, focus, sleep, and memory overstate the published clinical evidence. In a small pilot randomized controlled trial of ISF in mild-to-moderate Alzheimer's disease (n=11), adherence was reported above 86.1% of intended treatment days, and cognitive and structural MRI outcomes showed only exploratory non-significant tendencies, with authors concluding that potential efficacy must be tested in larger trials. Larger efficacy trials in Alzheimer's disease and major depressive disorder remain in protocol or preliminary stages.

8

Supported by research

0:01:10David Perlmutter (host)supportedhigh

There are currently no meaningful disease-modifying treatments for neurodegenerative diseases like Alzheimer's and Parkinson's disease that address the underlying disease process.

"despite all the attention on targeting proteins, misfolded proteins like beta-amyloid for Alzheimer's, we still don't really have any meaningful treatments for diseases like Alzheimer's and Parkinson's disease per se. And we certainly can treat symptoms, but as it relates to treating the underlying issue, we're falling short." (said at 0:01:10)

The host's statement accurately reflects the current consensus in scientific and clinical literature regarding disease-modifying therapies (DMTs) for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). For Alzheimer's disease, although anti-amyloid monoclonal antibodies (such as lecanemab, donanemab, and aducanumab) have received regulatory approvals based on statistical slowing of cognitive decline and amyloid clearance, systematic reviews and meta-analyses show that these statistical differences fail to meet established minimal clinically important difference (MCID) thresholds for meaningful clinical benefit (PMID: 38253509, PMID: 39332901). For Parkinson's disease, phase II and III clinical trials targeting alpha-synuclein and other proposed disease-modifying pathways have consistently failed to show clinical efficacy or slow disease progression (PMID: 42459575, PMID: 42098470). Consequently, while symptomatic treatments exist, established therapies that meaningfully alter the underlying disease trajectory remain elusive.

0:01:38David Perlmutter (host)supportedmoderate

Dysregulated microglia can drive neuroinflammation and brain degeneration long before clinical symptoms appear.

"what's really exciting is the emerging research on what I've called the microglia. These are the brain's immune cells. And when they're balanced, they are protecting, they are repairing. But when they're dysregulated—and we can talk about why that happens, and we do talk about it in the book—they can drive inflammation and lead to brain degeneration often long before symptoms appear." (said at 0:01:38)

Microglia function as the resident immune cells of the central nervous system, contributing to neuroprotection, surveillance, and synaptic maintenance under homeostatic conditions. However, when chronically or aberrantly activated, microglia drive neuroinflammatory pathways that promote synaptic loss and neuronal degeneration. In vivo neuroimaging studies using positron emission tomography (PET) targeting translocator protein (TSPO) have demonstrated that microglial activation and neuroinflammation occur in prodromal and preclinical stages of neurodegenerative disorders, such as Alzheimer's disease, and correlate with brain atrophy and subsequent cognitive decline.

0:02:01David Perlmutter (host)supportedmoderate

Microglial cells are deeply influenced by daily lifestyle factors including nutrition, sleep, and environment.

"these microglial cells are deeply influenced by your day-to-day lifestyle choices, your nutrition, your sleep, your environment." (said at 0:02:01)

Extensive preclinical and translational literature demonstrates that microglia (the brain's resident immune cells) are dynamically modulated by modifiable lifestyle factors, including diet, sleep loss/deprivation, exercise, and environmental conditions. Reviews synthesizing evidence across neuroscience indicate that poor diet, chronic sleep deprivation, and environmental stressors can trigger pro-inflammatory microglial activation and synaptic pruning deficits, whereas beneficial lifestyle interventions (such as balanced nutrition, adequate sleep, and environmental enrichment) support microglial homeostatic functions and neuroprotection.

0:22:11David Perlmutter (host)supportedmoderate

Visible stroboscopic 40 Hz light stimulation can cause side effects such as nausea and headaches.

"Most use what's called stroboscopic light, and that's the type of light that flashes, and you can see the flashing, and that can cause nausea, it can cause headaches." (said at 0:22:11)

Visible stroboscopic 40 Hz light stimulation is known to cause visual discomfort, eye strain, headaches, and nausea, which has prompted the development of alternative modalities such as invisible spectral flicker (ISF) to improve tolerability and adherence during extended exposure protocols. Clinical investigations of 40 Hz sensory stimulation note that while gamma neuromodulation protocols are generally safe overall without serious adverse events, visible stroboscopic flicker presents notable discomfort and tolerability challenges compared to non-visible or continuous light paradigms.

0:41:42David Perlmutter (host)supportedhigh

The APOE4 genetic marker is associated with cognitive decline.

"You may carry genetic markers associated with cognitive decline like as we've talked about APOE4, but possession doesn't equal expression." (said at 0:41:42)

Large meta-analyses of prospective cohort studies consistently demonstrate that carrying the apolipoprotein E epsilon 4 (APOE4) allele is significantly associated with accelerated cognitive decline and an increased risk of progression to objective cognitive impairment and dementia.

0:41:55David Perlmutter (host)supportedmoderate

Lifestyle, nutrition, and metabolic health can influence gene expression related to brain health and cognitive resilience.

"Your lifestyle, your nutrition and metabolic health, all the things that we talked about here on the podcast can powerfully influence which genes are turned on and which stay quiet." (said at 0:41:55)

The claim is supported by scientific evidence. Lifestyle factors—including physical exercise, nutrition, and metabolic state—influence gene transcription and epigenetic regulation (such as DNA methylation, histone modifications, and non-coding RNAs) in pathways related to brain health, synaptic plasticity, neuroinflammation, and cognitive resilience.

  • supports: Epigenetic and Neurogenomic Mechanisms Linking Physical Activity to Brain Plasticity and C… (Genes 2026) · cited 1x in the literature
    "Available evidence, derived predominantly from animal studies and supported by more limited, often indirect human data, indicates that physical activity induces epigenetic modifications, including changes in DNA methylation, histone modifications, and microRNA expression, which contribute to lasting changes in exercise-responsive genes involved in brain plasticity. These adaptations include the upregulation of key neuroplasticity-related mediators that support neurogenesis, synaptic plasticity, angiogenesis, and metabolic adaptation, alongside the downregulation of pathways linked to neuroinflammation, oxidative stress, and apoptotic signalling." (abstract, results, passage verified)
    pubmedfull study (doi)
  • supports: Mind-body exercise as epigenetic modulators: Rewiring neural circuits for stress resilienc… (IBRO neuroscience reports 2026)
    "Recent studies suggest that MBEs may influence neurobiological systems through epigenetic regulation, including DNA methylation, histone modifications, and non-coding RNAs. This review critically evaluates the current empirical evidence linking MBEs to epigenetic changes and explores their potential downstream effects on neural circuitry and cognitive outcomes. Special attention is given to biomarkers such as brain-derived neurotrophic factor (BDNF), glucocorticoid receptor (NR3C1), and FKBP5, which are involved in stress regulation and neuroplasticity." (abstract, passage verified)
    pubmedfull study (doi)
0:42:15David Perlmutter (host)supportedmoderate

Inflammation, methylation imbalances, and oxidative stress are key drivers of brain dysfunction and neurodegeneration.

"focused on inflammation, methylation, oxidation, oxidative stress, things that we routinely discuss here on the podcast that are the key drivers of basically what makes a good brain go bad." (said at 0:42:15)

Published narrative reviews and mechanistic syntheses confirm that neuroinflammation, oxidative stress, and methylation dysregulation (including impaired DNA methylation and one-carbon/folate metabolism) are central pathological mechanisms driving brain dysfunction and neurodegenerative disorders such as Alzheimer's and Parkinson's diseases.

1:04:00David Perlmutter (host)supportedmoderate

Cold plunging, sauna use, and exercise act as hormetic stressors that build resilience.

"That, you know, it's why we cold plunge, we sauna, exercise, etc., because that level of stress actually builds resilience." (said at 1:04:00)

The biological concept of hormesis describes a biphasic dose-response relationship in which exposure to mild-to-moderate, intermittent physical stressors (such as exercise, heat exposure/sauna, and cold stress) triggers cellular and physiological adaptation pathways. These include the activation of heat shock proteins, antioxidant defenses (e.g., Nrf2 pathways), mitochondrial biogenesis, and neuroplasticity factors, which collectively enhance cellular and organismal resilience against subsequent challenges.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.